"PATIENT_ID","LINE_NUMBER","LINE_NAME","START_DATE","END_DATE","LINE_TYPE","IS_MAINTENANCE","ADD_EXEMPTION","SUB_EXEMPTION","GAP_EXEMPTION","NAME_EXEMPTION","LINE_END_REASON","ENHANCED_COHORT","INDEX_DATE"
3,1,"Carboplatin",2018-04-19,2018-04-19,"mono",FALSE,FALSE,FALSE,FALSE,FALSE,"Last row hit","NSCLC",2018-04-19
101,1,"Pembrolizumab",2018-04-19,2018-12-27,"mono",FALSE,FALSE,FALSE,FALSE,FALSE,"New line started with new drugs","NSCLC",2018-04-19
101,2,"Carboplatin,Pembrolizumab,Pemetrexed",2019-01-24,2019-04-18,"combo",FALSE,FALSE,FALSE,FALSE,FALSE,"Last row hit","NSCLC",2018-04-19
2,1,"Nivolumab",2018-01-14,2018-02-18,"mono",FALSE,FALSE,FALSE,FALSE,FALSE,"New line started with new drugs","NSCLC",2018-01-14
2,2,"Carboplatin,Nivolumab",2018-03-04,2018-04-29,"combo",FALSE,FALSE,FALSE,FALSE,FALSE,"New line started with new drugs","NSCLC",2018-01-14
2,3,"Cetuximab",2018-05-14,2018-06-18,"mono",FALSE,FALSE,FALSE,FALSE,FALSE,"Passed discontinuation gap","NSCLC",2018-01-14
2,4,"Durvalumab",2018-11-12,2018-11-26,"mono",FALSE,FALSE,FALSE,FALSE,FALSE,"Last row hit","NSCLC",2018-01-14
4,1,"Carboplatin,Pembrolizumab,Pemetrexed",2020-01-01,2020-05-01,"combo",FALSE,FALSE,FALSE,FALSE,FALSE,"Last row hit","NSCLC",2020-01-01
1111,1,"Pembrolizumab",2019-01-01,2019-02-01,"mono",FALSE,FALSE,FALSE,FALSE,FALSE,"Passed discontinuation gap","NSCLC",2019-01-01
1111,2,"Pembrolizumab",2019-07-01,2019-09-01,"mono",FALSE,FALSE,FALSE,FALSE,FALSE,"New line started with new drugs","NSCLC",2019-01-01
1111,3,"Cisplatin,Pemetrexed",2019-10-01,2019-11-08,"combo",FALSE,FALSE,FALSE,FALSE,FALSE,"Passed discontinuation gap","NSCLC",2019-01-01
1111,4,"Cisplatin,Pemetrexed",2020-05-02,2020-05-16,"combo",FALSE,FALSE,FALSE,FALSE,FALSE,"Last row hit","NSCLC",2019-01-01
2222,1,"Cisplatin,Nivolumab",2019-01-01,2019-02-01,"combo",FALSE,FALSE,FALSE,FALSE,FALSE,"Passed discontinuation gap","NSCLC",2019-01-01
2222,2,"Nivolumab",2019-07-01,2019-10-01,"mono",FALSE,FALSE,FALSE,FALSE,FALSE,"New line started with new drugs","NSCLC",2019-01-01
2222,3,"Carboplatin,Pembrolizumab,Pemetrexed",2020-01-01,2020-02-01,"combo",FALSE,FALSE,FALSE,FALSE,FALSE,"Passed discontinuation gap","NSCLC",2019-01-01
2222,4,"Pembrolizumab",2020-07-01,2020-10-01,"mono",FALSE,FALSE,FALSE,FALSE,FALSE,"Last row hit","NSCLC",2019-01-01
3333,1,"Pembrolizumab,Pemetrexed",2020-01-01,2020-05-08,"combo",FALSE,FALSE,FALSE,FALSE,FALSE,"Entering continuation maintenance therapy","NSCLC",2020-01-01
3333,1,"Pemetrexed",2020-03-02,2020-05-08,"mono",TRUE,FALSE,FALSE,FALSE,FALSE,"Last row hit","NSCLC",2020-01-01
3344,1,"Carboplatin,Pembrolizumab,Pemetrexed",2020-01-01,2020-05-08,"combo",FALSE,FALSE,FALSE,FALSE,FALSE,"Entering continuation maintenance therapy","NSCLC",2020-01-01
3344,1,"Pemetrexed",2020-03-02,2020-05-08,"mono",TRUE,FALSE,FALSE,FALSE,FALSE,"Last row hit","NSCLC",2020-01-01
4444,1,"Pembrolizumab",2020-01-01,2020-02-02,"mono",FALSE,FALSE,FALSE,FALSE,FALSE,"New line started with new drugs","NSCLC",2020-01-01
4444,1,"Pemetrexed",2020-03-02,2020-05-08,"mono",TRUE,FALSE,FALSE,FALSE,FALSE,"Last row hit","NSCLC",2020-01-01
5555,1,"Erlotinib",2020-01-01,2021-05-15,"mono",FALSE,FALSE,FALSE,TRUE,FALSE,"Last row hit","NSCLC",2020-01-01
6666,1,"Cisplatin,Pemetrexed",2019-10-01,2019-11-08,"combo",FALSE,FALSE,TRUE,FALSE,FALSE,"Passed discontinuation gap","NSCLC",2019-10-01
6666,2,"Carboplatin,Pemetrexed",2020-05-02,2020-05-16,"combo",FALSE,FALSE,FALSE,FALSE,FALSE,"Last row hit","NSCLC",2019-10-01
67,1,"Carboplatin,Pemetrexed",2020-05-16,2020-05-16,"combo",FALSE,FALSE,FALSE,FALSE,FALSE,"Last row hit","NSCLC",2020-05-16
